2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRoCS)open access
- Authors
- 이찬호; 강민용; 곽철; 김성한; 김정권; 박재영; 서성일; 서일영; 서준교; 송완; 송채린; 육형동; 이상철; 이형호; 정진수; 정창욱; 조정기; 최창일; 추설호; 한준현; 황의창; 김미소; 김찬; 최석환; 홍성후
- Issue Date
- Aug-2022
- Publisher
- 대한비뇨기종양학회
- Keywords
- Cytoreductive surgical procedures; Nephrectomy; Renal cell carcinoma; Immunotherapy; Targeted therapy
- Citation
- 대한비뇨기종양학술지, v.20, no.3, pp.151 - 162
- Indexed
- KCI
- Journal Title
- 대한비뇨기종양학술지
- Volume
- 20
- Number
- 3
- Start Page
- 151
- End Page
- 162
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/171502
- DOI
- 10.22465/kjuo.2022.20.3.151
- ISSN
- 2234-4977
- Abstract
- Purpose: The Korean Renal Cancer Study Group (KRoCS) provides consensus recommendations on the role of cytoreductive nephrectomy (CRN) in patients with metastatic renal cell carcinoma (mRCC).
Materials and Methods: A group of mRCC experts from the Korean Urological Oncology Society convened at the 2021 KRoCS meeting on CRN for mRCC.
Results: The consensus document was developed to address 4 questions related that were judged to be the most relevant to patient care: (1) Is there a role for CRN in patients planning targeted therapy? (2) Is there a role for CRN in patients planning immuno-oncology agents? (3) When is the optimal time of CRN in patients planning systemic treatment? (4) What is the ideal patient selection for CRN? The panelists have come up with following consensus. For mRCC patients, CRN should be considered only in those with IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) favorable and intermediate risk disease, regardless of the systemic treatment plans. Timing of CRN should consider the risk group as well as the number of risk factors, but is generally recommended for after assessing the degree of response to initial systemic treatment. Patients with good performance status, limited metastatic burden on top of resectable primary tumor are candidates recommended for CRN with or without metastasectomy with priority.
Conclusions: In conclusion, there is still a role for CRN in the multimodality treatment of mRCC. Careful patient selection is of paramount importance. As the treatment landscape of mRCC continues to change, the role of CRN in the current immuno-oncology era will require more exploration.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 비뇨의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/171502)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.